Regeneron and Sanofi ride the wave of success; partner again in new cancer antibody deal; Regeneron regains full rights
Regeneron Pharmaceuticals Inc. and Sanofi continued to build on a very successful relationship by entering into a new drug development deal, this time focusing on PD-1 and other immuno-oncology antibodies over a period of five years (with the possibility of a three-year extension).
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.